ID   Y79/EDR
AC   CVCL_A5SR
DR   Wikidata; Q107117559
RX   DOI=10.3969/j.issn.1673-713X.2017.04.002;
RX   PubMed=32143590;
CC   Population: Caucasian.
CC   Doubling time: 14.5 hours (DOI=10.3969/j.issn.1673-713X.2017.04.002).
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Eye, globe; UBERON=UBERON_0010230.
DI   NCIt; C7541; Retinoblastoma
DI   ORDO; Orphanet_790; Retinoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1893 ! Y-79
SX   Female
AG   2Y6M
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 29-06-23; Version: 5
//
RX   DOI=10.3969/j.issn.1673-713X.2017.04.002;
RA   Song W.-P., Zhang C.-Y., Zhang Y., Li Y., Cao R., Ye C., Zhang L.,
RA   Shao R.-G., Li L., Zhao J.-Y.;
RT   "Generation of etoposide-resistant subline of human retinoblastoma Y79
RT   cells and preliminary study of its resistance mechanism.";
RL   Zhongguo Yiyao Sheng Wu Jishu 12:297-302(2017).
//
RX   PubMed=32143590; DOI=10.1186/s12886-020-01348-6;
RA   Song W.-P., Zheng S., Yao H.-J., Zhou X.-F., Li R., Zhang C.-Y.,
RA   Zhao J.-Y., Wang L.-W., Shao R.-G., Li L.;
RT   "Different transcriptome profiles between human retinoblastoma Y79
RT   cells and an etoposide-resistant subline reveal a chemoresistance
RT   mechanism.";
RL   BMC Ophthalmol. 20:92.1-92.11(2020).
//